Barclays raised the firm’s price target on AbbVie to $175 from $170 and keeps an Overweight rating on the shares. The analyst remains positively biased on U.S. biopharmaceuticals into most Q4 setups, “leaning into recent winners.” The firm recommends weighting towards names with strong prescription trends, supportive guides and potential upside to 2024 numbers. It prefers Eli Lilly (LLY), Merck (MRK), AbbVie (ABBV) Regeneron (REGN). Barclays says Bristol-Myers (BMY) and Pfizer (PFE) are the “most challenged.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
- SHARx files defamation lawsuit against AbbVie
- AbbVie launches Produodopa in European Union
- AbbVie reports ‘positive’ results from Phase 2 trial of lutikizumab
- AbbVie and Umoja Biopharma partnering to develop in-situ CAR-T cell therapies
- CVS Caremark accelerates biosimilars adoption through formulary changes